



PATIENT INFORMATION (Complete or Fax Existing Chart)		PRESCRIBER INFORMATION	
Name: _____ DOB: _____		Prescriber Name: _____	
Address: _____		State License: _____	
City, State, Zip: _____		NPI #: _____ DEA: _____	
Phone: _____ Alt. Phone: _____		Address: _____	
Email: _____ SS#: _____		City, State, Zip: _____	
Gender: <input type="checkbox"/> M <input type="checkbox"/> F Weight: _____ (lbs) Ht: _____		Phone: _____ Fax: _____	
Allergies: _____		Office Contact: _____ Phone: _____	
INSURANCE INFORMATION – AND – Send a copy of the patient's prescription/insurance cards (front & back)			
Primary Insurance: _____		Secondary Insurance (If Applicable): _____	
Plan #: _____		Secondary Insurance: _____	
Group #: _____		Plan #: _____	
RX Card (PBM): _____		Group #: _____	
BIN: _____ PCN: _____		BIN: _____ PCN: _____	
CLINICAL INFORMATION			
Primary ICD-10 Code: _____		Diagnosis Description: _____	
Secondary ICD-10 Code: _____		Diagnosis Description: _____	
Hepatitis B Vaccination: <input type="checkbox"/> Yes <input type="checkbox"/> No		Patient on Methotrexate: <input type="checkbox"/> Yes <input type="checkbox"/> No	
Line Access: <input type="checkbox"/> PIV <input type="checkbox"/> Port <input type="checkbox"/> PICC <input type="checkbox"/> Midline			
RITUXIMAB ORDERS			
Prescription type: <input type="checkbox"/> New start <input type="checkbox"/> Restart <input type="checkbox"/> Continued therapy			
		Total Doses Received: _____ Date of Last Dose: _____	
Medication	Dose/Frequency	Refills	
<input type="checkbox"/> Rituxan® (rituximab) 100mg/10mL Vial	<input type="checkbox"/> 1,000mg IV x 2 Doses separated by 14 days, repeat every 24 weeks		
<input type="checkbox"/> Rituxan® (rituximab) 500mg/50mL Vial	<input type="checkbox"/> Other: _____		
<input type="checkbox"/> Riabni™ (rituximab-arrx) 100mg/10mL Vial	<input type="checkbox"/> 375mg/m2 once weekly for 4 weeks		
<input type="checkbox"/> Riabni™ (rituximab-arrx) 500mg/50mL Vial	<input type="checkbox"/> 500mg IV infusion separated by 2 weeks, followed by a 500mg IV infusion every 6 months		
	<input type="checkbox"/> Other: _____		
<input type="checkbox"/> Ruxience® (Rituximab-pvvr) 100mg/10mL Vial	<input type="checkbox"/> 1,000mg IV x 2 Doses separated by 14 days, repeat every 24 weeks		
<input type="checkbox"/> Ruxience® (Rituximab-pvvr) 500mg/50mL Vial	<input type="checkbox"/> Other: _____		
<input type="checkbox"/> Truxima® (rituximab-abbs) 100mg/10mL vial	<input type="checkbox"/> 1,000 mg intravenous every 2 weeks for 2 doses		
<input type="checkbox"/> Truxima® (rituximab-abbs) 500mg/50mL vial	<input type="checkbox"/> 375 mg/m2 intravenous infusion once weekly for 4 weeks		
	<input type="checkbox"/> Other: _____		
Pre-Medication	Dose/Strength	Directions	
<input type="checkbox"/> Acetaminophen	<input type="checkbox"/> 500mg	<input type="checkbox"/> Take 1-2 tablets PO prior to infusion or post-infusion as directed	
<input type="checkbox"/> Diphenhydramine	<input type="checkbox"/> 25mg IV/PO <input type="checkbox"/> 50mg IV/PO	<input type="checkbox"/> Take 1 tablet PO prior to infusion or as directed OR <input type="checkbox"/> Inject contents of 1 vial IV prior to infusion or as directed	
<input type="checkbox"/> Methylprednisolone	<input type="checkbox"/> 40mg <input type="checkbox"/> 100mg <input type="checkbox"/> 125mg	<input type="checkbox"/> Inject contents of 1 vial IV prior to infusion or as directed <input type="checkbox"/> Other: Inject 100mg IV 30 minutes prior to infusion	
<input type="checkbox"/> _____			
INFUSION REACTION ORDERS			

CONFIDENTIALITY STATEMENT: This facsimile and documents accompanying this transmission contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender at the address and telephone number set forth herein and arrange for return or destruction of the material. In no event should such material be read by anyone other than the named addressee, except by express authority of the sender to the named addressee.



Mild reaction protocol:

Diphenhydramine 25mg IV, one time, for pruritus.

If symptoms worsen, see orders for moderate to severe reactions.

Moderate reaction protocol:

Acetaminophen 650mg PO, one time, for pyrexia or rigors

Diphenhydramine 50mg IV, one time, for pruritus or urticaria

Famotidine 20mg IV, one time, for, for pruritus or urticaria

Methylprednisolone 125mg IV, one time, for respiratory or neurologic symptoms

If symptoms worsen, see interventions for severe reactions

Severe reaction protocol: (Call 911 if initiated):

Titrate oxygen via continuous flow per nasal cannula or face mask to maintain spO2 of greater than ninety-five percent (>95%)

Diphenhydramine 50mg IV, one time, for respiratory symptoms, edema, or anaphylaxis

Sodium Chloride 0.9% 500mL IV over 30-60 min, one time, for cardiovascular symptoms

Epinephrine 0.3mg/0.3mL IM into mis-anterolateral aspect of thigh of anaphylaxis, may repeat x1 in 5-15 minutes if symptoms are not resolved or worsen

FLUSHING & LOCKING ORDERS

Flushing Protocol (>66lbs/33kg)

PIV and Midline:

0.9% Sodium Chloride 2-5mL IV flush before and after each infusion

Implanted Port, PICC, Tunneled Catheter, and Non-tunneled Catheter:

0.9% Sodium Chloride 5mL IV flush before infusion/lab draw and 10mL IV flush after infusion/lab draw

Locking Protocol (>66lbs/33kg)

PIV and Midline:

Heparin Sodium 10 units/mL 1mL IV final flush post normal saline flush

PICC:

Heparin Sodium 10 units/mL 3mL IV final flush post normal saline flush

Implanted Port, Tunneled Catheter, and Non-tunneled Catheter:

Heparin Sodium 100 units/mL 3-5mL IV final flush post normal saline flush

**** May substitute Dextrose 5% in Water, or alternative, for 0.9% Sodium Chloride, when indicated due to incompatibility with medications being infused**

SIGNATURE

We hereby authorize Talis Healthcare LLC to provide all supplies and additional services (nursing/patient training) required to provide and deliver the medicine as prescribed in this referral.

X _____

Prescriber Signature

Date: _____

To ensure payment by insurance carrier, please include supporting clinical documentation for specified ICD 10 Code, demographic, and insurance information along with faxed order. Initial appointment will be verified upon insurance approval.

CONFIDENTIALITY STATEMENT: This facsimile and documents accompanying this transmission contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender at the address and telephone number set forth herein and arrange for return or destruction of the material. In no event should such material be read by anyone other than the named addressee, except by express authority of the sender to the named addressee.